Viking Therapeutics (NASDAQ:VKTX) stock is heading higher on Thursday as the clinical-stage biopharmaceutical company prepares to start another trial for its weight loss drug.Viking Therapeutics says that it’s ready to progress subcutaneous VK2735 into a Phase 3 clinical trial as a treatment for obesity and other metabolic disorders. This comes after the company reported positive results from a Phase 2 study in the first half of 2024.The results from the Phase 2 trial showed much promise with it meeting its ...